Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL388969 | 0.90 | PIP4K2A (0.33) | ALDH1A1 | |
| SCHEMBL391723 | 0.90 | ALDH1A1 (0.37) | ALDH1A1GAA | |
| SCHEMBL27774845 | 0.88 | AAK1 (0.32) | ALDH1A1GAA | |
| SCHEMBL394127 | 0.81 | LIMK1 (0.31) | — | |
| SCHEMBL2878483 | 0.81 | — | — | |
| SCHEMBL2923179 | 0.78 | TDO2 (0.39) | — | |
| SCHEMBL2947657 | 0.78 | POLQ (0.33) | ALDH1A1GAA | |
| SCHEMBL2878488 | 0.76 | CDK4 (0.32) | — | |
| SCHEMBL2878614 | 0.74 | JAK2 (0.37) | — | |
| SCHEMBL594142 | 0.74 | CA12 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101563342-B | Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer | LILLY CO ELI | 2012-09-05 | — | — | CN | disclosed |
| CN-101679396-B | Triazolylaminopyrimidine compounds | LILLY CO ELI | 2012-06-06 | — | — | CN | disclosed |
| US-8114872-B2 | Triazolyl aminopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8101628-B2 | Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| EP-2125793-B1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | LILLY CO ELI (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-05-27 | — | — | US | disclosed |
| US-20100076001-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY | 2010-03-25 | — | — | US | disclosed |
| CN-101679396-A | Triazolylaminopyrimidine compounds | LILLY CO ELI | 2010-03-24 | — | — | CN | disclosed |
| EP-2155735-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| CN-101563342-A | Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer | LILLY CO ELI (US) | 2009-10-21 | — | — | CN | disclosed |
| WO-2008144222-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076001-A1 | IMIDAZOLIDINONYL AMINOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | PLK1, BUB1B, BUB1 | ALDH1A1 3324/4885GAA 4852/4885 |
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | ALDH1A1 578/4885GAA 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.